Designed Cell-Penetrating Peptide Constructs for Inhibition of Pathogenic Protein Self-Assembly

Area of Science:

• Biochemistry and Molecular Biology
• Pharmacology and Therapeutics
• Neuroscience and Neurodegenerative Diseases

Background:

• Peptides offer unique pharmacological advantages, including high target specificity, biocompatibility, and cost-effective production.
• Peptide-based therapeutics, such as amyloid inhibitors, show significant promise for various diseases.
• Poor delivery of therapeutic peptides to target sites remains a major obstacle for clinical application.

Purpose of the Study:

• To review the development and potential of engineered cell-penetrating peptide (CPP) antagonists for targeting amyloidogenesis.
• To highlight CPP constructs designed to overcome delivery limitations and enhance therapeutic efficacy against amyloid-related disorders.

Main Methods:

• Review of recent research on engineering cell-penetrating peptides (CPPs).
• Analysis of CPP constructs designed to inhibit amyloid formation and associated cytotoxicity.
• Evaluation of CPPs' ability to facilitate delivery to target tissues, cells, and organelles.

Main Results:

• Engineered CPPs combine intrinsic peptide properties with potent amyloid inhibition and efficient delivery capabilities.
• CPP technology addresses the critical challenge of poor peptide bioavailability and targeted delivery.
• Promising CPP constructs have been identified for therapeutic intervention in amyloidogenic diseases.

Conclusions:

• Cell-penetrating peptides (CPPs) represent a significant advancement in peptide-based drug delivery for amyloid-related disorders.
• CPP antagonists offer a dual benefit of inhibiting amyloid aggregation and ensuring effective delivery.
• This approach holds potential for treating a range of conditions including Alzheimer's disease, prion diseases, Parkinson's disease, and cancer.